← Back to catalogue

Eversense 365 Mobile Application (iOS)

FDA UDI

Class II (US FDA UDI)

by Senseonics, Incorporated

Identity

Trade Name
Eversense 365 Mobile Application (iOS) FDA UDI
Generic Name
Implantable glucose monitoring system FDA UDI
Device Name
Eversense 365 Mobile Application for iOS is a software application that runs on a mobile device (e.g., smart phone or tablet) and displays glucose data, trend information, and alerts. FDA UDI
Model / Reference
FG-5503-06-300 FDA UDI
Description
Eversense 365 Mobile Application for iOS is a software application that runs on a mobile device (e.g., smart phone or tablet) and displays glucose data, trend information, and alerts. FDA UDI

Identifiers

Catalog Number
FG-5503-06-300 FDA UDI
Primary DI / UDI-DI
00817491024268 FDA UDI
510(k) Number
K241335 FDA UDI
FDA Product Code
SBA FDA UDI
GMDN Term
Implantable glucose monitoring system FDA UDI

Classification

Device Class
Class II FDA UDI
Regulation Number
862.1357 FDA UDI
Commercial Distribution
In Commercial Distribution FDA UDI

Clinical & Handling

Sterile

No

FDA UDI

Single Use

Yes

FDA UDI

Implantable

Yes

FDA UDI

Contains Latex

No

FDA UDI

Prescription Use

Yes

FDA UDI

Over-the-Counter

No

FDA UDI

Convenience Kit

No

FDA UDI

Combination Product

No

FDA UDI

HCT/P

No

FDA UDI

Premarket Exempt

No

FDA UDI

Lot / Batch Number

Yes

FDA UDI

Serial Number

No

FDA UDI

Expiration Date

No

FDA UDI

Manufacturing Date

No

FDA UDI

Category: Implantable glucose monitoring system

Eversense 365 Mobile Application (iOS) by Senseonics, Incorporated — Class II — FDA UDI — listed in FDA GUDID — regulatory data on deviCERTS

Similar devices

Also classified as Implantable glucose monitoring system.

Cleared under the same submission

Authorization Coverage (1 country)

Regulatory Authorizations

United States Pending data

FDA UDI

Is this your device? Claim it to add documentation and request validation.

Manufacturer

Sources (1)

  • FDA UDI 3100c37c-f310-4309-8500-1d535ce374bb 36 fields · synced May 30, 2026